Core Viewpoint - The resilience of small and medium-sized listed companies in China continues to stand out, with effective investor relations management becoming essential for overcoming development bottlenecks and solidifying market value foundations [1][14] Group 1: Activities and Engagement - The Beijing Stock Exchange Association (北上协) has organized the "Shareholders Are Coming" series for two consecutive years, focusing on small and medium-sized listed companies with a market value below 10 billion yuan [2][14] - Over 800 participants, including institutional investors, analysts, and media representatives, engaged in face-to-face communication with 12 small and medium-sized listed companies [1][2] - The activities utilized a "reverse roadshow" approach, allowing investors to visit production facilities and R&D labs, providing a hands-on understanding of company operations [1][13] Group 2: Industry Focus Areas - The series highlighted three key sectors: biomedicine, smart transportation, and digital technology, showcasing the industrial characteristics of companies in Beijing [2] - In biomedicine, companies like Tianzhihang and Nuocheng Jianhua demonstrated innovative products and advancements in healthcare technology [3][4] - Smart transportation was represented by companies like Jiexun Feihong, which showcased their achievements in digital traffic solutions and defense technology [7] - Digital technology was emphasized through companies like Yubang Electric and Zhongke Jincai, focusing on digital infrastructure and AI-driven services [10][11] Group 3: Company Highlights - Tianzhihang's surgical robot is the first globally to cover major orthopedic surgeries, achieving international advanced levels in precision and efficiency [3] - Nuocheng Jianhua's innovative therapies have gained regulatory approval, positioning the company as a leader in hematological and solid tumor treatments [4] - Sanyuan Gene's new smart manufacturing facility incorporates AI technology, marking a significant advancement in gene engineering drug development [5] - Ganjin Pharmaceutical's insulin products dominate the market, reflecting strong competitive positioning [6] - Aibono's medical technology products fill domestic gaps and challenge international monopolies in the vision care sector [6] Group 4: Investor Relations and Market Development - The activities serve as a critical platform for small and medium-sized companies to showcase their value and engage directly with investors, addressing the challenges of information asymmetry [14][15] - The initiative aligns with national policies aimed at enhancing investor protection and promoting long-term capital market development [15] - The ongoing series of activities is set to continue, fostering deeper investor understanding of company strengths and industry prospects [15]

Core Viewpoint - The company reported strong revenue growth in 2024, but faced a decline in net profit in Q1 2025 due to market pressures from centralized procurement and reduced surgical volumes [1][2]. Financial Performance - In 2024, the company achieved revenue of 1.41 billion yuan, a year-on-year increase of 48.24%, and a net profit of 388 million yuan, up 27.77% [1]. - For Q1 2025, revenue was 357 million yuan, reflecting a year-on-year growth of 15.07%, while net profit decreased to 93 million yuan, down 10.05% [1]. Product Performance - Revenue from artificial crystalline lenses reached 588 million yuan in 2024, growing by 17.66%, with sales volume increasing by 44.93% [2]. - The company’s revenue from myopia control products grew by 20.79%, driven by the introduction of various new products [2]. R&D Investment and New Business Growth - The company increased R&D investment to 160 million yuan in 2024, a rise of 20.80%, representing 11.33% of total revenue [3]. - The contact lens business saw significant growth, with revenue reaching 426 million yuan, a staggering increase of 211.84% [3]. Market Outlook - The company is projected to achieve revenues of 1.81 billion yuan, 2.26 billion yuan, and 2.79 billion yuan for 2025-2027, with respective growth rates of 28.44%, 24.91%, and 23.12% [4]. - Expected net profits for the same period are 467 million yuan, 600 million yuan, and 778 million yuan, with growth rates of 20.21%, 28.55%, and 29.63% [4]. Earnings Per Share - The projected EPS for the years 2025, 2026, and 2027 are 2.46 yuan, 3.17 yuan, and 4.10 yuan respectively [5].